Dyne's $305M of­fer­ing; Nanobi­otix de­lays Ph2 read­out

Last year
News Briefing

Ot­su­ka ter­mi­nates Alzheimer's ag­i­ta­tion drug af­ter failed Phase 3

Last year
R&D

Bio­gen makes $1.15B buy for ARCH's HI-Bio to ex­pand im­munol­o­gy pipeline

Last year
Deals

Boehringer In­gel­heim, OSE Im­munother­a­peu­tics ex­pand part­ner­ship be­yond can­cer

Last year
Deals

Evotec ends gene ther­a­py busi­ness, shuts down fa­cil­i­ty in Aus­tria

Last year
Pharma
Cell/Gene Tx

See you at BIO: Chi­na ten­sions, fix­ing gene ther­a­py’s busi­ness mod­el, and the stop-start mar­ket re­cov­ery

Last year
Editor's note

Dai­ichi Sankyo to open two new re­search sites in Cam­bridge and Mu­nich this year

Last year
R&D

Oral drug shows promise in di­a­bet­ic mac­u­lar ede­ma as biotech touts an­ti-VEGF in­jec­tion al­ter­na­tive

Last year
R&D

Ver­sant has a new obe­si­ty biotech. As­traZeneca has the op­tion to buy it

Last year
Financing
Startups

No­vo Nordisk looks be­yond weight loss and di­a­betes to ex­pand in new ill­ness­es

Last year
Pharma

NIH drafts pol­i­cy on en­sur­ing ac­cess to new drugs fund­ed by tax­pay­ers

Last year
R&D
FDA+

Sen­a­tors strike bi­par­ti­san tone on more phar­ma patent re­forms

Last year
Pharma
FDA+

Sen. Wyden ques­tions Pfiz­er over tax rate as part of on­go­ing in­ves­ti­ga­tion

Last year
Pharma
FDA+

With $5B in Chi­na sales, As­traZeneca dou­bles down on Chi­nese bio­phar­ma in­no­va­tion

Last year
China
Pharma

Bris­tol My­er­s' sub­cu­ta­neous ver­sion of Op­di­vo gets ear­li­er PDU­FA date

Last year
Pharma
FDA+

Hims’ push in­to com­pound­ed GLP-1 drugs risks scruti­ny from No­vo Nordisk

Last year
Law
Health Tech

As­traZeneca counts on ‘dif­fi­cult-to-copy’ ther­a­pies for big 2030 goal and be­yond

Last year
R&D
Pharma

Lyra to lay off 75% of its work­ers; Dupix­ent nears COPD de­ci­sion

Last year
News Briefing

With a fresh $100M, Monte Rosa CEO de­tails plans to move sev­er­al mol­e­c­u­lar glues in­to the clin­ic

Last year
Financing

Sanofi, Ope­nAI, For­ma­tion Bio an­nounce AI drug de­vel­op­ment part­ner­ship

Last year
Deals
R&D

AI biotech Ex­sci­en­tia to trim near­ly a quar­ter of work­force, fol­low­ing pipeline cut and CEO fir­ing

Last year
People
AI

Al­tru­Bio se­cures $225M for an up­dat­ed ver­sion of its ul­cer­a­tive col­i­tis drug

Last year
Financing
Startups

Lil­ly makes an­oth­er ra­dio­phar­ma move in col­lab­o­ra­tion with Ak­tis On­col­o­gy

Last year
Startups
Deals

FDA lifts par­tial clin­i­cal hold on Lari­mar’s Friedre­ich’s atax­ia treat­ment

Last year
R&D
FDA+
First page Previous page 154155156157158159160 Next page Last page
A service from the Financial Times